Showing 5961-5970 of 9076 results for "".
- Tapinarof Shows Rapid Itch and Skin Improvement in Atopic Dermatitishttps://practicaldermatology.com/news/tapinarof-shows-rapid-itch-and-skin-improvement-in-atopic-dermatitis/2486493/New pooled Phase 3 data presented at the American Academy of Dermatology (AAD) 2026 Annual Meeting highlight the rapid onset and consistent efficacy of tapinarof cream 1% (VTAMA; Organon) in patients with moderate-to-severe atopic dermatitis (AD), including children as young as 2 years. Th
- Nail Psoriasis and Real-World Data Highlight Tildrakizumab’s Staying Powerhttps://practicaldermatology.com/news/nail-psoriasis-and-real-world-data-highlight-tildrakizumabs-staying-power/2486482/Two posters presented at the American Academy of Dermatology (AAD) Annual Meeting highlight both clinical trial efficacy and real-world durability of tildrakizumab, an interleukin (IL)-23 p19 inhibitor, in patients with moderate-to-severe plaque psoriasis.
- TYK2-JAK1 Inhibitor Treatment Promising for Individuals with Refractory Dermatomyositishttps://practicaldermatology.com/news/tyk2-jak1-inhibitor-treatment-promising-for-individuals-with-refractory-dermatomyositis/2486481/Results from the Phase 3 VALOR trial presented at the American Academy of Dermatology (AAD) 2026 Annual Meeting revealed that individuals with re
- Study: Elevated Obstetric Risks in Women With Hidradenitis Suppurativahttps://practicaldermatology.com/news/study-finds-elevated-obstetric-risks-in-women-with-hidradenitis-suppurativa/2486444/Women with hidradenitis suppurativa (HS) had significantly higher odds of hypertensive disorders (OR = 1.81), cesarean delivery (OR = 1.34), and preterm birth (OR = 1.20) compared with those without HS, according to a systematic review and meta-analysis presented a
- Lebrikizumab Shows Durable Efficacy Through 4 Years in Atopic Dermatitishttps://practicaldermatology.com/news/lebrikizumab-shows-durable-efficacy-through-4-years-in-atopic-dermatitis/2486468/Long-term data from the Phase 3b ADlong study show that lebrikizumab provides sustained skin clearance and itch relief for up to four years in patients with moderate-to-severe atopic dermatitis (AD), according to findings presented at the American Academy of Dermatology (AAD) 2026 Annual Meeting.
- Nemolizumab Shows Efficacy in Pediatric Atopic Dermatitishttps://practicaldermatology.com/news/nemolizumab-shows-efficacy-in-pediatric-atopic-dermatitis/2486457/Nemolizumab, an IL-31 receptor alpha (IL-31Rα) antagonist, demonstrated favorable pharmacokinetics, sustained efficacy, and a consistent safety profile in children aged 2 to 11 years with moderate-to-severe atopic dermatitis (AD), according to Phase 2 data presented by Linda Stein Gold, MD, at th
- Upadacitinib Shows Strong Hair Regrowth in Alopecia Areatahttps://practicaldermatology.com/news/upadacitinib-shows-strong-hair-regrowth-in-alopecia-areata/2486456/Upadacitinib demonstrated robust efficacy in both adolescents and adults with severe alopecia areata (AA), with particularly strong responses observed in younger patients, according to a subgroup analysis of two Phase 3 trials presented by Melinda Gooderham, MD, MSc, at the American Academy of De
- Combination Therapy Improves Outcomes in Psoriatic Arthritis With Obesityhttps://practicaldermatology.com/news/combination-therapy-improves-outcomes-in-psoriatic-arthritis-with-obesity/2486455/Combination therapy with ixekizumab and tirzepatide demonstrated superior disease control compared with ixekizumab alone in adults with psoriatic arthritis (PsA) and overweight or obesity, according to Phase 3b TOGETHER-PsA results presented by Joseph F. Merola, MD, MMSc, at the American Academy
- IL-15 Blockade Plus Phototherapy Shows Promise in Vitiligohttps://practicaldermatology.com/news/il-15-blockade-plus-phototherapy-shows-promise-in-vitiligo/2486454/Targeting IL-15 with ordesekimab in combination with narrowband ultraviolet B (nbUVB) phototherapy led to greater repigmentation in patients with non-segmental vitiligo, according to results from a randomized, placebo-controlled trial presented by Brett King, MD, PhD, at the American Academy of D
- Zasocitinib Demonstrates Biologic-Level Efficacy in Psoriasishttps://practicaldermatology.com/news/zasocitinib-demonstrates-biologic-level-efficacy-in-psoriasis/2486453/Zasocitinib, a selective oral tyrosine kinase 2 (TYK2) inhibitor, demonstrated rapid and robust efficacy with a consistent safety profile in moderate-to-severe plaque psoriasis, according to Phase 3 LATITUDE-PsO-3001 and LATITUDE-PsO-3002 trial results presented by Melinda Gooderham, MD, MSc, at